{
    "id": 3508,
    "fullName": "MTOR act mut",
    "impact": "unknown",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MTOR act mut indicates that this variant results in a gain of function in the Mtor protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 2475,
        "geneSymbol": "MTOR",
        "terms": [
            "MTOR",
            "FRAP",
            "FRAP1",
            "FRAP2",
            "RAFT1",
            "RAPT1",
            "SKS"
        ]
    },
    "variant": "act mut",
    "createDate": "03/05/2015",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6350,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, 28% (12/43) of metastatic renal cell carcinoma patients who responded to rapalogs, Afinitor (everolimus) or Torisel (temsirolimus), harbored inactivating TSC1, TSC2 mutations and/or activating MTOR mutations, compared to 11% (4/36) in patients who did not respond to therapy (PMID: 26831717).",
            "molecularProfile": {
                "id": 3315,
                "profileName": "MTOR act mut"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5537,
                    "pubMedId": 26831717,
                    "title": "Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26831717"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6353,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, 28% (12/43) of metastatic renal cell carcinoma patients who responded to rapalogs, Afinitor (everolimus) or Torisel (temsirolimus), harbored inactivating TSC1, TSC2 mutations and/or activating MTOR mutations, compared to 11% (4/36) in patients who did not respond to therapy (PMID: 26831717).",
            "molecularProfile": {
                "id": 3315,
                "profileName": "MTOR act mut"
            },
            "therapy": {
                "id": 936,
                "therapyName": "Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5537,
                    "pubMedId": 26831717,
                    "title": "Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26831717"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3315,
            "profileName": "MTOR act mut",
            "profileTreatmentApproaches": [
                {
                    "id": 2773,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "MTOR act mut"
                },
                {
                    "id": 685,
                    "name": "mTOR Inhibitor",
                    "profileName": "MTOR act mut"
                },
                {
                    "id": 2774,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "MTOR act mut"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}